World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
54872
World Ranking
9854
National Ranking
956

Overview

Nagahiro Saijo is affiliated with AstraZeneca (United Kingdom) and has contributed to research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their scholarly work is distributed across several subfields including Pulmonary and Respiratory Medicine, Oncology, Geriatrics and Gerontology, Physiology, and Cancer Research.

Their research interests focus on topics such as Frailty in Older Adults, Nutrition and Health in Aging, Lung Cancer Diagnosis and Treatment, Renal Cell Carcinoma Treatment, Cancer Genomics and Diagnostics, and Pancreatic and Hepatic Oncology Research.

Saijo has coauthored studies with several frequent collaborators, notably Hiroshi Katayama, Junki Mizusawa, Haruhiko Fukuda, Shinichiro Nakamura, and K. Nakamura.

Their publications appear mainly in the Japanese Journal of Clinical Oncology and also in UNC Libraries, reflecting engagement with journals that focus on clinical oncology and clinical research issues.

Significant papers authored or coauthored by Saijo include:

  • Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A), 2021, Japanese Journal of Clinical Oncology
  • Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study, 2020, Japanese Journal of Clinical Oncology
  • Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics, 2020, UNC Libraries

Best Publications

  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

    Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson

  • The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

    Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta

  • Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

    Kazumasa Noda;Yutaka Nishiwaki;Masaaki Kawahara;Shunichi Negoro

  • Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

    Masahiro Fukuoka;Yi Long Wu;Sumitra Thongprasert;Patrapim Sunpaweravong

  • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

    Y Ohe;Y Ohashi;K Kubota;T Tamura

  • Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

    Minoru Takada;Masahiro Fukuoka;Masaaki Kawahara;Takahiko Sugiura

  • The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

    William D. Travis;Hisao Asamura;Alexander A. Bankier;Mary Beth Beasley

  • Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

    Masahiro Fukuoka;Kiyoyuki Furuse;Nagahiro Saijo;Yutaka Nishiwaki

  • Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

    Riichiroh Maruyama;Yutaka Nishiwaki;Tomohide Tamura;Nobuyuki Yamamoto

  • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

    Roy S Herbst;Yan Sun;Wilfried E E Eberhardt;Paul Germonpré

  • Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

    Osamu Kawai;Genichiro Ishii;Kaoru Kubota;Yukinori Murata

  • Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

    J.-C. Soria;A. Mauguen;M. Reck;A. B. Sandler

  • Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

    Hironobu Minami;Kimie Sai;Mayumi Saeki;Yoshiro Saito

  • UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.

    Kimie Sai;Mayumi Saeki;Yoshiro Saito;Shogo Ozawa

  • Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

    Y. Kataoka;T. Mukohara;H. Shimada;N. Saijo

  • Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

    Koichi Goto;Yukito Ichinose;Yuichiro Ohe;Nobuyuki Yamamoto

  • Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

    Shinji Atagi;Masaaki Kawahara;Akira Yokoyama;Hiroaki Okamoto

  • The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

    Frank C. Detterbeck;Wilbur A. Franklin;Andrew G. Nicholson;Nicolas Girard

  • The Development and Clinical Use of a Beam ON-LINE PET System Mounted on a Rotating Gantry Port in Proton Therapy

    Teiji Nishio;Aya Miyatake;Takashi Ogino;Keiichi Nakagawa

Frequent Co-Authors

Tomohide Tamura
Tomohide Tamura St. Luke's International Hospital
Yuichiro Ohe
Yuichiro Ohe National Cancer Centre
Kazuto Nishio
Kazuto Nishio Kindai University
Yutaka Nishiwaki
Yutaka Nishiwaki Tokyo Medical University
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Jun-ichi Sawada
Jun-ichi Sawada University of Shizuoka
Teruhiko Yoshida
Teruhiko Yoshida National Cancer Research Institute, UK
Yoshiro Saito
Yoshiro Saito Tohoku University
Shogo Ozawa
Shogo Ozawa Iwate Medical University
Atsushi Ohtsu
Atsushi Ohtsu Juntendo University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degree options can open up new routes for advancing your healthcare career or transitioning into medical fields. For nurses aiming for leadership roles, the quickest DNP program options offer a fast-track to a Doctor of Nursing Practice, balancing academic intensity with flexibility for working professionals.

If balancing clinical commitments is a concern, some candidates may prefer a DNP program without clinical hours. These programs allow students to focus more on leadership, administration, or education rather than direct patient care.

Those earlier in their nursing journey might consider fast track LPN programs, which can help students quickly gain practical nursing skills and enter the workforce. Once established, nurses with a passion for mental health can explore psych nurse practitioner programs to specialize further.

Each of these pathways provides a flexible, efficient way to enhance qualifications while managing career and personal commitments.

Best Scientists Citing Nagahiro Saijo

Trending Scientists

Recently Published Articles